Bayer (XTRA:BAYN) reported that the U.S. FDA accepted its supplemental New Drug Application for KERENDIA for CKD patients without diabetes.
The filing is backed by Phase III trial data that Bayer says showed kidney and cardiovascular benefits in non diabetic CKD patients.
KERENDIA is already approved in the U.S. for adults with chronic kidney disease associated with type 2 diabetes.
The FDA’s acceptance of Bayer’s sNDA for KERENDIA in non diabetic CKD patients is a key development to weigh. We have also spotted 4 other big wins worth knowing about at Bayer.
This move by Bayer into broader CKD treatment is part of a wider push in healthcare where other drug developers are also active. 124 healthcare AI stocks
XTRA:BAYN Earnings & Revenue Growth as at Oct 2026
Bayer, a €41.8 billion life science group active across Europe, the Americas and Asia, has been pushing deeper into prescription therapies, where chronic diseases like kidney conditions sit alongside its broader pharmaceuticals portfolio. This global reach gives the KERENDIA franchise exposure to a wide range of healthcare systems and treatment guidelines.
How could this FDA step broaden KERENDIA’s market opportunity for Bayer?
The sNDA covers adults with CKD without diabetes on standard care, a population not included in KERENDIA’s current U.S. approvals. FIND CKD enrolled 1,584 such patients and showed a statistically significant 0.7 mL/min/1.73 m²/year difference in eGFR decline versus placebo, plus a benefit on a kidney cardiovascular composite outcome, pointing to a potentially wider treated pool if regulators agree.
Does this change the Bayer Narrative investors have been watching?
The Narrative around Bayer highlights new labels and approvals for KERENDIA as a key pharmaceutical catalyst that can help offset patent losses and support longer term earnings quality. This CKD without diabetes filing fits directly into that storyline by leaning on late stage data to extend an existing drug franchise rather than relying only on completely new assets.
See how these catalysts shape Bayer’s path to a €58.22 fair value.
What should investors watch next to see if this KERENDIA story progresses?
The critical signpost now is the FDA’s decision on this sNDA for CKD without diabetes, including the timing and any label wording around the kidney and cardiovascular endpoints from FIND CKD. Attention will also sit on how closely clinical practice guidelines and prescribing patterns eventually track that final label in real world use.
The Bayer detail most holders scroll past
There is a separate story sitting in the long range analyst models for Bayer, where the projected income statements and cash flows point to an outcome that current headlines barely hint at. See where analysts expect Bayer to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BAYN.DE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com